The impact of depressive symptoms in early Parkinson disease

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Neurology

• Publication date

  2007-07-24

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1212/01.wnl.0000268695.63392.10PMID 17581943PMCID PMC2031220
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic and Statistical Manual of Mental Disorders

  2008cited by this paper
• Physiology of MPTP Tremor

  2008cited by this paper
• Effect of age on geriatric depression scale performance in Parkinson's disease

  2007cited by this paper
• A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

  2007cited by this paper
• A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

  2006cited by this paper
• Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH Work Group

  2006cited by this paper
• Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.

  2006cited by this paper
• A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.

  2006cited by this paper
• Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.

  2006cited by this paper
• The under-recognition of depression in Parkinson’s disease

  2006cited by this paper
• Screening older adults for depression in primary care settings.

  2006cited by this paper
• Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease.

  2006cited by this paper
• Outcomes of Minor and Subsyndromal Depression among Elderly Patients in Primary Care Settings

  2006cited by this paper
• Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy.

  2006cited by this paper
• The effect of depression on motor function and disease severity of Parkinson's disease.

  2006cited by this paper
• The motor performance test series in Parkinson's disease is influenced by depression

  2005cited by this paper
• Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease

  2004cited by this paper
• Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition.

  2004cited by this paper
• Treatment of Depression in Primary Care: Where We Are, Where We Can Go

  2004cited by this paper
• Prevalence, etiology, and treatment of depression in Parkinson's disease.

  2003cited by this paper
• Recognition and Treatment of Depression in Parkinson's Disease

  2003cited by this paper
• Analyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS.

  2003cited by this paper
• Non-recognition of depression and other non-motor symptoms in Parkinson's disease.

  2002cited by this paper
• Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study

  2000cited by this paper
• What contributes to quality of life in patients with Parkinson's disease?

  2000cited by this paper
• Depression in classic versus akinetic‐rigid Parkinson's disease

  1998cited by this paper
• The occurrence of depression in Parkinson's disease. A community-based study.

  1996cited by this paper
• Depression and disability in Parkinson's disease.

  1996cited by this paper
• A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease.

  1992cited by this paper
• An estimate of the incidence of depression in idiopathic Parkinson's disease.

  1992cited by this paper
• The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease

  1991cited by this paper
• Depression and disability in Parkinson's disease: a follow-up of 132 cases

  1988cited by this paper
• The association of ventral tegmental area histopathology with adult dementia.

  1988cited by this paper

• Intranasally Delivered Mesenchymal Stem Cells Reverses Prodromal Non-Motor Deficits and Nigral Loss in a Parkinson’s Disease Mouse Model

  2026cites this paper
• QUALIDADE DO SONO EM PACIENTES COM DOENÇA DE PARKINSON: ANÁLISE BASEADA NA APLICAÇÃO DA ESCALA PDSS-2

  2026cites this paper
• Factors associated with higher caregiver burden among informal caregivers of Parkinson’s disease: A systematic review

  2025cites this paper
• Dissociation of Clinical Outcomes and CSF Proteinopathy Biomarkers in Parkinson’s Disease: Cognitive–Affective Dissociation with Specificity for Tau

  2025cites this paper
• Development and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson’s Disease

  2025cites this paper
• Association between Physical Activity, Depression Severity and Parkinson's Symptoms in Older Adults with Parkinson's disease: A Cross-Sectional Study

  2025cites this paper
• Изучение воздействия синэстрола на функциональную активность нейронов базолатеральной амигдалы на модели болезни Паркинсона

  2025cites this paper
• Meaning in life and Parkinson's disease: Evidence from a 17-year study across 14 countries.

  2025cites this paper
• Treatment Approaches To Anxiety and Depression in Parkinson’s Disease

  2025cites this paper
• Trajectories and Predictors of Activity Participation Among People with Parkinson’s Disease: A 3-year Longitudinal Study

  2025cites this paper
• Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson disease

  2024cites this paper
• Influence of Depression on the Quality of Life in Patients With Parkinson's Disease in Southwest Nigeria

  2024cites this paper
• Effects of Manual Therapy on Parkinson’s Gait: A Systematic Review

  2024cites this paper
• The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis

  2024cites this paper
• Aerobic exercise improves depressive symptoms in the unilateral 6-OHDA-lesioned rat model of Parkinson’s disease

  2024cites this paper
• Impact of Parkinsonism comorbid depression on cognitive functions

  2024cites this paper
• Association of Baseline Depression and Anxiety with Longitudinal Health Outcomes in Parkinson's Disease

  2024cites this paper
• Self‐ and study partner–reported cognitive decline in older adults without dementia: The role of α‐synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative

  2024cites this paper
• Assessing the impact of immersive virtual reality technology on the psychological recovery of patients with Parkinson’s disease depression: study protocol of a randomized controlled trial

  2024cites this paper
• Advanced glycation end products consumption and the decline of functional capacity in patients with Parkinson's disease: Cross-sectional study

  2024cites this paper
• Drug-Induced Gambling Disorder: Epidemiology, Neurobiology, and Management

  2023cites this paper
• Identification and Experimental Validation of Parkinson’s Disease with Major Depressive Disorder Common Genes

  2023cites this paper
• Investigation of non-invasive focused ultrasound efficacy on depressive-like behavior in hemiparkinsonian rats

  2023cites this paper
• Association of physical activity with the risk of Parkinson's disease in depressive disorder: A nationwide longitudinal cohort study.

  2023cites this paper
• Neuronavigated repetitive transcranial magnetic stimulation improves depression, anxiety and motor symptoms in Parkinson’s disease

  2023cites this paper
• Psychometrics and diagnostics of the Italian version of the Beck Depression Inventory-II (BDI-II) in Parkinson’s disease

  2023cites this paper
• Parkinson's Disease Related Depression and Anxiety: A 22-Year Bibliometric Analysis (2000-2022)

  2023cites this paper
• Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson’s disease

  2023cites this paper
• Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders

  2023cites this paper
• Time to initiation of symptomatic treatment in untreated Parkinson disease in the Parkinson progression marker initiative cohort: A 10-year follow up.

  2023cites this paper
• EVALUATION OF THE PRESENCE OF RE-EMERGENT TREMOR AND ITS EFFECT ON CLINICAL FEATURES IN PARKINSON'S DISEASE

  2023cites this paper
• Early Detection of Depression in Parkinson's Disease: Psychometrics and Diagnostics of the Spanish Version of the Beck Depression Inventory.

  2023cites this paper
• Treating Parkinson’s Disease with Depression from the Perspective of “Depression Syndrome”

  2023cites this paper
• The pathobiological basis of depression in Parkinson disease: challenges and outlooks

  2022cites this paper
• Research on depression in Parkinson disease: A bibliometric and visual analysis of studies published during 2012–2021

  2022cites this paper
• Altered Intra- and Inter-Network Connectivity in Drug-Naïve Patients With Early Parkinson’s Disease

  2022cites this paper
• Depression assessment in people with Parkinson's disease: The combination of acoustic features and natural language processing

  2022cites this paper
• Therapeutic Approaches to Non-Motor Symptoms of Parkinson's Disease: A Current Update on Preclinical Evidence

  2022cites this paper
• Inflammatory markers and depression in Parkinson’s disease: a systematic review

  2022cites this paper
• Effects of Exercise on Depressive Symptoms in Patients With Parkinson Disease

  2022cites this paper
• A Review of Diagnostic Techniques for Parkinson’s Disease

  2022cites this paper
• Depression in Parkinson's Disease: A Narrative Review

  2022cites this paper
• Targeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models

  2022cites this paper
• Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment

  2022cites this paper
• Associations of Sleep Disorders With Depressive Symptoms in Early and Prodromal Parkinson’s Disease

  2022cites this paper
• Effect of Physical Activity on Depression in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis

  2022cites this paper
• From Perceived Stress to Demoralization in Parkinson Disease: A Path Analysis

  2022cites this paper
• Depressive symptoms before and after Parkinson’s diagnosis—A longitudinal analysis

  2022cites this paper
• Mapping neuromodulatory systems in Parkinson’s disease: lessons learned beyond dopamine

  2022cites this paper
• A Pilot Study of Telehealth Mindfulness-Based Cognitive Therapy for Depression in Parkinson’s Disease

  2022cites this paper
• Frequency of Depressive Disorders in Parkinson’s Disease: A Systematic Review and Meta-Analysis

  2022cites this paper
• Modulation of histone deacetylase, the ubiquitin proteasome system, and autophagy underlies the neuroprotective effects of venlafaxine in a rotenone-induced Parkinson's disease model in rats.

  2022cites this paper
• Exploration of Parkinson’s Disease Symptomatology Subtypes From the Caregiver Perspective: Implications for Caregiver Burden, Depression, and Anxiety

  2021cites this paper
• Clinical Trials for Depression , Anxiety , Fatigue , and Apathy in Parkinson’s Disease

  2021cites this paper
• Activities of daily living as a longitudinal moderator of the effect of autonomic dysfunction on anxiety and depression of Parkinson's patients

  2021cites this paper
• Health-Related Quality of Life for Parkinson’s Disease Patients and Their Caregivers

  2021cites this paper
• Longitudinal association between housing accessibility and activities of daily living: the role of self-e cacy and control in people ageing with Parkinson’s disease

  2021cites this paper
• ResearchOnline@ND ResearchOnline

  2021cites this paper
• Psychiatric Comorbidities Affect the Hospitalization Course of Parkinson’s Disease Patients: A Cross-Sectional Inpatient Study

  2021cites this paper
• Baicalein alleviates depression-like behavior in rotenone- induced Parkinson's disease model in mice through activating the BDNF/TrkB/CREB pathway.

  2021cites this paper
• Downregulation of astroglial glutamate transporter GLT-1 in the lateral habenula is associated with depressive-like behaviors in a rat model of Parkinson's disease.

  2021cites this paper
• Clinical Trials In Parkinson's Disease

  2021cites this paper
• Sociability‐based fitness approach in Parkinson’s disease: Comparison with conventional rehabilitation

  2021cites this paper
• Impact of subthreshold depression on health-related quality of life in patients with Parkinson’s disease based on cognitive status

  2021cites this paper
• Parkinsonism

  2021cites this paper
• The Growing Role of Cognitive Behavior Therapy in the Treatment of Parkinson’s Disease

  2021cites this paper
• Depressive symptoms in selected neurological disorders

  2020cites this paper
• Depressive symptoms in selected neurological disorders

  2020cites this paper
• Longitudinal change in autonomic symptoms predicts activities of daily living and depression in Parkinson’s disease

  2020cites this paper
• for , , , and in Parkinson’s

  2020cites this paper
• Investigating the Convergent Mechanisms between Major Depressive Disorder and Parkinson’s Disease

  2020cites this paper
• Psychiatric Symptoms in Patients and Caregivers with Parkinson’s Disease

  2020cites this paper
• Suicide.

  2020cites this paper
• Blockade of GABA transporter-1 and GABA transporter-3 in the lateral habenula improves depressive-like behaviors in a rat model of Parkinson's disease.

  2020cites this paper
• Symptom burden among individuals with Parkinson disease: A national survey.

  2020cites this paper
• Basal Ganglia

  2020cites this paper
• Depression in Parkinson's disease: Perspectives from an Australian cohort.

  2020cites this paper
• Telephone-based cognitive behavioral therapy for depression in Parkinson disease

  2020cites this paper
• Telephone-Based, Clinician-Guided Self-Help Cognitive Behavioral Therapy for Depression in Parkinson's Disease (dPD): The Responder Cases of "Alice" and "Carl," and the Nonresponder Cases of "Ethan" and "Gary"

  2020cites this paper
• Alterations of Interhemispheric Functional Connectivity in Parkinson’s Disease With Depression: A Resting-State Functional MRI Study

  2020cites this paper
• Electroacupuncture alleviates Parkinson disease and regulates the expression of brain-gut peptides

  2020cites this paper
• Neuropsychiatric Disorders in Parkinson’s Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?

  2020cites this paper
• Pingchan granule for depressive symptoms in parkinson's disease: A randomized, double-blind, placebo-controlled trial.

  2020cites this paper
• The path linking disease severity and cognitive function with quality of life in Parkinson’s disease: the mediating effect of activities of daily living and depression

  2020cites this paper
• Prevalence of and Severity of Depression among Parkinson Disease Patients

  2020cites this paper
• Emerging Concepts of Motor Reserve in Parkinson’s Disease

  2020cites this paper
• Palliative Care for Parkinson’s Spectrum Disorders: an Emerging Approach

  2020cites this paper
• Brief Psychiatric Screening Questionnaire in Parkinson's Disease

  2019cites this paper
• Mood Effects After Deep Brain Stimulation for Parkinson's Disease: An Update

  2019cites this paper
• Depression in Parkinson’s Disease: Aspects of the Psychopathological Structure and Nosological Qualification

  2019cites this paper
• Depression Screening from Voice Samples of Patients Affected by Parkinson’s Disease

  2019cites this paper
• Cognitive behavioral therapy improves diverse profiles of depressive symptoms in Parkinson's disease

  2019cites this paper
• Longitudinal association between housing accessibility and activities of daily living: the role of self-efficacy and control in people ageing with Parkinson’s disease

  2019cites this paper
• Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease

  2019cites this paper
• International Journal of Medical and Biomedical Studies (IJMBS)

  2019cites this paper
• Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics.

  2019cites this paper
• Effectiveness of imaging genetics analysis to explain degree of depression in Parkinson’s disease

  2019cites this paper
• Drug treatment strategies for depression in Parkinson disease

  2019cites this paper
• Variation of Non-Motor Neurological Symptoms of Parkinson’s disease Patients

  2019cites this paper
• Cognitive and behavioral assessment in Parkinson’s disease

  2019cites this paper